This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date, and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced, and non-promotional.

General Instructions

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should question be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title of each item must precede the answer.

2. The term “Issuer” includes the Issuer and any of its subsidiaries.

3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing and accelerating the commercialization of its proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor, and assess cancer treatment early, accurately, and cost-effectively. The Company has developed its annual roadmap and continues to hold regular management meetings to discuss all aspects of the Company’s business plan. It executes action items that result from these meetings.

Management’s primary areas of focus continue to include:

• Accelerating commercialization efforts of its lab-developed test (LDT) for early lung cancer detection following promising interim retrospective data presented at various oncology conferences across N. America and Europe.

• These results were statistically significant and continued to generate interest from leading institutions in the US, France, Germany and South America, which the company intends to pursue post-launching its assay initially in Canada following certification of its Quebec-based lab and data readout on its lung cancer clinical studies.

• Complete data analytics on the large-scale early lung cancer multimodal study (5,400 patients) across 7 hospitals based in Quebec after the successful completion of plasma samples and analysis using BioMark’s metabolomics assay. Preliminary results from the retrospective, cancer-confirmed patient cohort, which includes an expanded non-cancer control group, have been analyzed, and the robust results met all assay performance metrics—high sensitivity and specificity. The company is discussing with key opinion leaders at the Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) on where and when to publish the data. Additional data on the prospective lung cancer screening cohort continues to be collected in 2026 as detailed in the clinical design. Pending the outcome of the results, the company intends to present it at a major cancer symposium.

• Seek deeper collaborations with several high-profile USA medical institutions and introduce the company to insurance companies (payers), regulatory experts, advocacy groups, and biopharma partners as its early lung cancer LDT commercialization efforts gather momentum. The US market is strategic due to its large addressable lung cancer screening market for at-risk populations (estimated at over 16 million annually). The market remains mostly untapped as there’s only a 5-6% penetration of image-based screening for the population at risk of developing lung cancer. In addition, the federal government is encouraging expanded accessibility for lung cancer screening initiatives across different states, especially for rural communities that are resource – constrained.

• Continue to seek and secure the necessary funding to unlock the full potential of its diagnostic platform. The Company will continue to target non-dilutive funding opportunities from Canadian, European, and U.S. agencies and foundations to support key initiatives, including:

• • Optimizing our lab operations

  • Achieving clinical lab certification

  • Gathering additional real-world evidence

  • Embedding more AI and ML capabilities

  • Driving U.S. expansion and payor endorsement

  • Fueling business development

  • Conducting clinical studies to extend the platform to additional cancers and define its role in treatment response assessment

  • Filing patents to protect discoveries and strategically expand patent estate

2. Provide a general overview and discussion of the activities of management.

• Despite persistent ongoing geopolitical tensions and resulting global economic challenges, the company is strategically positioned to navigate these hurdles and capitalize on the significant opportunities within the oncology molecular diagnostics sector. Our core expertise in metabolomics and AI-driven biomarker discovery directly addresses the need for earlier (stage shifting), accessible, and more precise cancer detection. While navigating a cautious investment landscape and a rapidly evolving technology environment with a scarce talent market, the Company has proactively implemented agile strategies and resilient operational and financial systems to counteract these headwinds. Furthermore, recognizing the transformative power of technology, the Company is strategically building a robust AI infrastructure through key collaborations, aiming to leverage advanced analytics to enrich assay results and enhance its cancer diagnostics capabilities. The company is committed to continuous innovation and disciplined execution to realize the full potential of these opportunities for our stakeholders.

• BioMark operates within a challenging economic environment that significantly impacts small-cap diagnostic companies. The funding landscape shows recovery with continued selectivity for investment. This environment particularly challenges emerging diagnostic companies like BioMark, as investors continue to prioritize clinical-stage companies with proven concepts. Investor caution and a skilled labor shortage in bioinformatics are impacting the industry. Financing timelines are extended, making fundraising particularly challenging for small-cap diagnostic companies.

• On April 1, 2026, BioMark’s management held a follow-up meeting with Roche Diagnostics Canada to present its vision for oncology and explore potential collaboration on the Open Molecular Solution, following Roche’s visit to BioMark’s Quebec City laboratory. A non-disclosure agreement was signed on April 17, 2026, and Dr. Jeff Haince, Chief Scientific Officer, visited Roche’s Montreal laboratory on April 21, 2026. Discussions and collaboration efforts are ongoing during June, and the outcome of any progress will be duly reported as progress is made.

• On June 9, 2026, BioMark announced that the United States Patent and Trademark Office (USPTO) have issued a Notice of Patent Allowance for Application No. 18/304,741, titled “Method of Detecting Lung Cancer.” The allowed patent covers the proprietary use of urine to detect lung cancer, assess treatment response, screen at-risk populations, and evaluate drug efficacy using a highly specific panel of polyamine metabolites and other critical analytes.

• On June 23, 2026, BioMark announced that it had officially received formal patent allowances from both the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) covering its proprietary technology for the early detection of lung cancer. These patent allowances represent a significant milestone in protecting BioMark’s precision oncology platform and support the Company’s commercialization strategy. The patented technology includes the core biomarker panel and algorithm currently incorporated into BioMark’s minimally invasive blood test for the early detection of non-small cell lung cancer (NSCLC). Designed to improve screening uptake and enable detection at the earliest, most treatable stages of disease, the technology has the potential to address a major unmet clinical need, as lung cancer remains the leading cause of cancer-related mortality worldwide. Additional patent allowances covering this same patent family are expected shortly in the United States, Japan, and China, further strengthening BioMark’s global intellectual property portfolio and commercial positioning.

• BioMark and its strategic collaborators were invited to participate in the Manitoba Lung Association (MLA) Annual General Meeting, held on June 22, 2026, in Winnipeg, Manitoba. The meeting brought together key stakeholders to discuss future lung health priorities and provided an opportunity to establish the foundation for potential strategic collaborations focused on early lung cancer detection and related public health initiatives.

Drs. Tappia and Mr. Ramjiawan were invited to submit a proposal under the MLA Operating Grant Program. BioMark and its collaborators subsequently submitted a grant application entitled “Optimizing Blood Collection, Processing, and Cold-Chain Logistics for Metabolomics-Based Early Lung Cancer Detection in a Manitoba Radon-Exposed Population.” The proposed study aims to optimize pre-analytical sample handling procedures to support the reliable implementation of metabolomics-based lung cancer diagnostics in high-risk populations. The Company will provide an update once the grant review process has been completed and funding decisions have been announced.

• The 16th Annual Association for Mass Spectrometry & Advances in the Clinical Lab (MSACL) Conference & Exhibits will be held at the Bonaventure Hotel Conference Centre in Montreal, Canada, from October 4 – 9, 2026. BioMark’s Chief Scientific Officer, Dr. Jeff Haince, will attend this premier international scientific meeting to engage with leading researchers, clinicians, diagnostic companies, and industry partners.

The conference provides an excellent opportunity to showcase BioMark’s recent scientific and technological achievements, including its proprietary platform that integrates advanced mass spectrometry with laser thermal desorption technology for precision biomarker detection and early cancer diagnostics. The meeting also offers opportunities to explore potential research collaborations, strategic partnerships, technology licensing, and commercialization initiatives. Appropriate follow-up discussions will be undertaken after the conference with interested parties.

MSACL’s mission is to accelerate the translation of innovative analytical technologies from pre-clinical research into routine clinical practice to improve patient care. While the organization has a strong focus on mass spectrometry, it also serves as a multidisciplinary forum for emerging analytical platforms, data analytics, artificial intelligence, and other technologies that advance precision medicine and clinical diagnostics.

• Following BioMark’s October 7, 2025, announcement regarding its participation in the landmark HANSE lung cancer screening trial in Germany, significant progress has been achieved. By the end of June 2026, about 7000 samples had been successfully analyzed at BioMark’s laboratory in Quebec City. The study met all key execution yardsticks, including recruitment, visit completion, biospecimen collection, imaging adherence, and end‑to‑end sample processing, underscoring the feasibility of implementing an advanced, risk‑adapted lung cancer screening program at scale.

• BioMark’s strategic collaboration with Harrisburg University under the leadership of Dr. Maria Vaida, Assistant Professor of Data Science, along with her Ph.D. student team, created a semantic embedded deep learning framework that provides an additive predictive signal across linear, kernel based, tree based, and neural network models from blood plasma using metabolites that significantly enhances biologic assay performance and diagnostic capabilities. Several papers are in the pipeline for the submissions to relevant and important journals throughout the year. The most recent two papers titled “Smoking-Stratified Signal Decomposition and Feature Selection Improves Never-Smoker Cancer Classification in a Combined Lung–Breast Metabolomics Cohort” and “CDR-Informed Graph Neural Network for Plasma Metabolomics in Lung Cancer and Pulmonary Neuroendocrine Neoplasms” have been submitted for publication and are currently under review. Once published the link to the article will be available on the company’s website.

• The Company has been approached by multiple international institutions and investment brokers regarding potential partnerships and licensing opportunities aligned with its commercialization strategy. While discussions remain at a preliminary stage, any material developments will be disclosed in future updates. In addition, BioMark received interest from two U.S. states exploring potential business expansion opportunities. Any substantive progress in these discussions will be announced in subsequent monthly reports.

• BioMark continues to entertain discussions with various financial institutions, accredited individual investors, and government agencies to secure non-dilutive funding, favourable loans, and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise, to advance its expansion strategy in the USA and internationally as well as for general corporate purposes.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists, and trademarks.

On June 9, 2026, BioMark announced that the United States Patent and Trademark Office (USPTO) have issued a Notice of Patent Allowance for Application No. 18/304,741, titled “Method of Detecting Lung Cancer.”

On June 23, 2026, BioMark announced that the Company has officially received formal patent allowances from both the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) for its groundbreaking lung cancer early detection technology, patent titled “METHOD OF DIAGNOSING EARLY-STAGE NON-SMALL CELL LUNG CANCER”.

The Issuer continues to file trademarks and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of the anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The trends and risks that are likely to impact the Issuer are discussed in the Form 51-102F1 Management’s Discussion & Analysis Annual Report for the Year Ended March 31, 2025.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 3^rd, 2026